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Composition of personalized and standard nutritional mixtures
in patients on home parenteral nutrition
C Scanzano1,2, R Iacone1,2, L Alfonsi1, MR Galeotalanza1, D Sgambati1, E Pastore1, A D’Isanto1, F Fierro1, F Contaldo1 and L Santarpia1
BACKGROUND/OBJECTIVES: The compounding of personalized parenteral nutrition mixtures (PPNMs) for home parenteral
nutrition (HPN) gives the possibility to better satisfy nutritional requirements for patients in selected clinical conditions. The
objective of this study was to compare the composition of PPNMs prescribed in selected cases, by a practitioner nutritionist,
with that of industrially manufactured standard parenteral nutrition mixtures (SPNMs).
SUBJECTS/METHODS: Two hundred and ninety-eight patients (151 men, 147 women, aged 17–87 years) on HPN, followed
up in 2011 at our Center, were retrospectively recruited.
RESULTS: Industrially manufactured SPNMs were prescribed in 230 (77.2%) patients, whereas compounded PPNMs were prescribed
in 68 (22.8%). Formulation of PPNMs, adjusted for body weight, did not signiﬁcantly differ from SPNMs as regards total daily calorie
amount, but was signiﬁcantly different as far as nutrient composition is concerned (Po0.01). Analysis on the daily amount of
nutrients per kg of body weight and per patient disease showed that 16/34 (47%) benign chronic intestinal failure (CIF) patients,
47/233 (20%) cancer patients and 5/31 (16%) patients grouped as ‘having other diseases’ needed personalized mixtures (in PPNMs
4–9 nutrients were signiﬁcantly different from those in SPNMs). Moreover, in CIF patients receiving PPNMs, frequent changes in the
formulation (mean 6 times per year, range 1–28) were necessary.
CONCLUSIONS: Our data suggest that, presently, PPNMs cannot be completely replaced by SPNMs owing to special needs in
macro and/or micronutrients of some patients and/or the necessity of frequent changes in the nutritional mixture composition,
at least until stabilization of clinical and metabolic conditions.
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INTRODUCTION
Parenteral nutrition (PN) is indicated in patients who cannot be fed
by enteral route, such as those with intestinal failure or obstruc-
tion.1–3 Patients needing PN must be evaluated by a specialized
nutritional team4–6 to establish their ﬂuid, electrolytes, and macro-
and micronutrient requirements.3,7–9 Nutritional guidelines are a
valid reference for a safe PN support formulation;10 however,
nutrient requirements can widely vary from one patient to another
and for the same patient in time,11,12 even according to patient’s
gender, age, weight, hematobiochemical exams, mostly depending
on clinical conditions, evolution and characteristics of primary
disease. PN consists in intravenous administration of nutrients
as elementary components that can also be performed for long
periods at home.13,14 Nutritional mixtures may be compounded
(namely prepared in hospital pharmacies and personalized
according to patient requirement) or standard (manufactured
by pharmaceutical industries). For patients without relevant
comorbidities, standard parenteral nutrition mixtures (SPNMs) are
often adequate to correct nutrient deﬁciencies and their related
complications.15 However, for patients with particular comorbidities
(heart failure, chronic renal failure, hepatic failure), as well as for
critically ill and/or catabolic patients or for patients with benign
chronic intestinal failure (CIF), that is, chronic inﬂammatory bowel
diseases and short bowel syndrome, PPNMs are often required.14
Aim of the study
This retrospective study compares the formulation of PPNMs and
SPNMs, both prescribed by a physician specialized in clinical
nutrition at our nutritional center. The study does not aim to
debate the appropriateness of the parenteral nutritional mixtures
prescriptions, but only to evaluate the differences in nutrient
composition, also according to the different diseases treated.
PATIENTS AND METHODS
Patients and medical intervention
Out of 648 patients (303 men, 345 women, aged 16–97 years) followed at
the Home Artiﬁcial Nutrition Unit of Federico II University Hospital in
Naples from January to December 2011,16 298 were on home parenteral
nutrition (HPN). Patients were grouped into three groups: (1) oncologic;
(2) patients with CIF; (3) patients affected by ‘other diseases’, such
as neurologic disease, malabsorption after bariatric surgery, gastrectomy,
cystic ﬁbrosis, intractable diarrhea for intestinal infections, primary
hypo- or a-gammaglobulinemia, necrotizing enterocolitis, high-output
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enterocutaneous ﬁstulas, intestinal motility disorders, pancreatitis, graft-
versus-host disease and intractable vomiting in pregnant.
Case history, physical examination, anthropometric measurements and
biochemical exams were mostly performed on a Day Hospital basis, and in
a minority of patients during hospitalization.
Data collection
Demographic, clinical and anthropometric data of HPN patients, days of
therapy and formulation of nutritional mixtures were routinely recorded by
the practitioner nutritionist in a dedicated electronic database, at the ﬁrst
visit of each patient and updated at each clinical control visit. Data for
the study were obtained from this dedicated database; no data concerning
the appropriateness of care were examined.
Nutritional assessment and indications for PN
Nutritional assessment and indication for PN were applied according to the
European Society for Clinical Nutrition and Metabolism (ESPEN) and the
Italian Society of Artiﬁcial Nutrition and Metabolism (SINPE) guidelines.3,8
PN was indicated in case of the impossibility to maintain an adequate
nutritional status by enteral route only, reduced bowel absorbent function,
impaired intestinal transit or mechanical bowel obstruction, severe bowel
ischemia, short bowel syndrome, high-output jejunal or ileal ﬁstulas.
Anthropometric measurements
Body weight and height were measured on a standard balance with an
attached ruler. Body weight was measured at the nearest 0.1 kg and height
at the nearest 1 cm. Body mass index was calculated as weight in kilograms
divided by the square of height in meters.
Compounding of PN mixtures
The compounding of PPNMs was in agreement with the ‘Good
Manufacturing Practices’ of Italian Pharmacopoeias17 and guidelines of
the ‘Societa` Italiana di Farmacia Ospedaliera e dei Servizi Farmaceutici
delle Aziende Sanitarie’ (SIFO) for PN,18 and was performed using an
automatic ﬁlling system (CARETRONIC, B Braun Italia SpA, Mirandola, Italy)
in a class A contamination area, achieved through the use of a horizontal
laminar ﬂow hood equipped with high-efﬁciency particulate air ﬁlters, in a
controlled environment with ﬁltrated air. Concentrate of trace elements
was regularly added as a supplement in PPNMs. Multivitamin formula for
infusion as lyophilized sterile powder was also added to the parenteral
mixture immediately before the infusion or was administered separately by
dissolving in physiological solution.
Industrial standard nutritional mixtures
Ready-to-use SPNMs were multichamber bags with three preﬁlled
compartments to mix at the time of infusion. These were used off the
shelf or as base for further aseptic additions, for example, vitamins, trace
elements, glutamine, etc. The formulation of four industrial parenteral
mixtures available at the Home Artiﬁcial Nutrition Unit of Federico II
University Hospital, used for 230 HPN patients, ranged as follows: energy
1000–1900 kcal; ﬂuid 1250–1920ml; nitrogen 5.4–10.2 g; amino acid
34–72g; glucose 97–225g; lipids 50–75 g; sodium 32–75mmol; potassium
24–52.5mmol; magnesium 4–6mmol; calcium 2–6mmol; phosphorus
11–22.5mmol. SPNMs of 750mOsm/l were used either for peripheral or
central venous access, whereas those with 1250mOsm/l osmolarity were
used only for central vein.
Statistical analysis
A post hoc statistical analysis of patient’s data receiving HPN from January
to December 2011 was performed using the Statistical Package for Social
Sciences version 13 (SPSS Inc., Chicago, IL, USA). Results are expressed as
mean±s.d., median and range (minimum–maximum) or 95% conﬁdence
interval (CI). Non-parametric tests were used because variables were not
normally distributed. Two-sided P-values o0.05 were always considered
statistically signiﬁcant.
RESULTS
In 2011, 298 patients (151 men, 147 women; age 17–87 years;
body weight 34.0–105.6 kg; body mass index 12.6–40.6 kg/m2)
received HPN (115 received oral nutritional support in addition),16
for a total of 14 772 PN mixtures delivered; of these, 10 161 (69%)
were SPNMs and delivered to 230 (77.2%) patients, and 4611
(31%) were PPNMs and prescribed to 68 (22.8%) patients. Median
HPN days of therapy per patient was 24 (range 8–357), in
particular 40 (8–357) for PPNMs and 20 (9–302) for SPNMs.
Number of patients, age, men/women ratio and days of parenteral
therapy per underlying disease are reported in Table 1. Primary
diseases, type of parenteral mixtures (PPNMs or SPNMs) received
and days of HPN therapy are summarized in Table 2. Table 3
reports the mean and 95% CI (adjusted for body weight) of
parenteral mixture components (compounded and industrial)
prescribed to the 298 HPN patients; for patients whose formula-
tion was modiﬁed over time, average value was used. When
comparing PPNM and SPNM formulations, all constituents resulted
statistically different (Po0.01, Mann–Whitney test), except for the
total calorie amount. In particular, average daily amounts of water,
nitrogen, amino acids, glucose, sodium, potassium, magnesium
and calcium were signiﬁcantly greater in the compounded
mixtures, whereas lipids and phosphates were signiﬁcantly lower.
Table 4 shows nutrients in parenteral mixtures (compounded and
industrial) per kg body weight per day prescribed in all patients,
classiﬁed according to their primary disease. Except for glucose
and potassium, in cancer patients signiﬁcant differences were
found between all other components of PPNMs (n¼ 47) when
compared with SPNMs (n¼ 186). In CIF patients, ﬂuid, nitrogen,
amino acids, sodium, potassium, magnesium and calcium were
statistically different when comparing PPNMs (n¼ 16) with SPNMs
(n¼ 18) (Po0.01, Mann–Whitney test), as well as glucose (Po0.05,
Mann–Whitney test). In patients grouped as having ‘other
Table 1. Number of patients, age, sex and HPN days of treatment of
298 patients (151 men, 147 women) followed in 2011, classified
according to their primary disease
Primary
disease
No. of
patients
(%)
Age
(years),
mean±s.d.
Men/
women
Days of therapy
median
and (range)
Cancer 233 (78.2) 63±12 122/111 20 (8–303)
CIF 34 (11.4) 55±16 18/16 65 (9–357)
Other diseases 31 (10.4) 59±20 11/20 20 (9–268)
Abbreviations: CIF, chronic intestinal failure; HPN, home parenteral
nutrition. Other disease: see Patients and Methods section.
Table 2. Type of parenteral mixture (compounded or industrial),
number of patients and HPN days of treatment in 298 patients
followed in 2011, classified according to primary disease
Primary disease PPNMs
No. of patients
Days of therapy,
median (range)
SPNMs
No. of patients
Days of therapy,
median (range)
Cancer 47
24 (8–303)
186
16 (9–296)
CIF 16
214 (12–357)
18
43 (9–302)
Other Diseases 5
17 (9–169)
26
22 (9–268)
Abbreviations: CIF, chronic intestinal failure; HPN, home parenteral
nutrition; PPNMs, personalized parenteral nutrition mixtures; SPNMs,
standard parenteral nutrition mixtures. Other disease: see Patients and
Methods section.
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diseases’, ﬂuid, sodium, magnesium and phosphorus in PPNMs
(n¼ 5) signiﬁcantly differed when compared with those in SPNMs
(n¼ 26) (Po0.01, Mann–Whitney test). Finally, in the 68 HPN
patients receiving compounded mixtures, the formulation
changed from 1 to 28 times during the 12-month period of
follow-up and, as shown in Table 5, the most frequent variations
were for CIF patients. On the other hand, only 5 out of
230 patients receiving SPNMs required formulation modiﬁcations
and these changes ranged between 1 and 2 in a year.
DISCUSSION
HPN reduces hospitalization rate and signiﬁcantly decreases the
National Health Service expense, as well as allowing patients to
live within their family and to return, at least in part, to usual living
habits.16,19,20 In 2011, 298 HPN patients were followed at the
Home Artiﬁcial Nutrition Unit of Federico II University Hospital in
Naples. As expected, most HPN patients suffered from cancer, while
CIF patients received HPN for the highest number of days. Generally,
for most cancer patients, PN was prescribed intermittently, mainly
during cycles of radio- or chemotherapy, while CIF patients needed
a continuous lifelong HPN supplementation. Patients grouped as
having ‘other diseases’ were generally treated continuously, until
their therapeutic goal was achieved.
When compared with PPNMs, ready-to-use SPNMs have a
reduced risk of contamination during preparation, lower costs
(cost-saving for pharmacy laboratories) and extended shelf
life.21,22 Moreover, a wide range of macronutrient concentrations
and volumes are also available, as well as the possibility,
depending on the osmolarity, to be infused through central or
peripheral venous accesses. Our data support these ﬁndings; 77%
HPN patients received SPNMs with several beneﬁts on clinical
outcomes. However for selected patients (23% of HPN patients), in
particular for most CIF patients and for some cancer and ‘other
diseases’ patients, the practitioner nutritionist prescribed PPNMs.
The majority of parenteral industrial mixtures allows the addition
of electrolytes; alternatively, patient needs could be satisﬁed by an
additional infusion therapy, both of which however are
endangered by a high risk of contamination.
Our analysis showed that 47% CIF, 20% cancer patients and
16% patients grouped as having ‘other disease’ were treated with
PPNMs for the necessity of frequent changes in the formulation of
the mixtures or to satisfy patients’ nutritional needs until clinical
and metabolical stabilization were reached. This was true, in
particular, in CIF patients.
When possible, an oral nutritional support was added to the PN
prescription to encourage ‘enterocyte feeding’ for a potential
weaning off PN. Out of 115 patients on HPN plus oral nutritional
support, 16 (14%) received personalized mixtures. Of these, 14 were
cancer patients and 2 CIF patients. As regards the formulation
changes, patients receiving PPNM plus oral nutritional support were
metabolically more stable than the others (16 patients: mean 1.6
(range 1–8) changes vs 52 patients: mean 3 (range 1–28)).
Nonetheless, in both groups, the composition of personalized
mixtures could not be replaced by the standard ones.
This study does not deal with the possible different outcomes
when using compounded or standard mixtures. A stimulating
analysis on the costs and on the infection rate resulting from the
administration of personalized compounded parenteral nutritional
mixtures have already been reported in literature, showing that
SPNMs are associated with lower costs than PPNMs with regard to
both PN acquisition and potential risks of bloodstream
infections.21,22
Table 3. Daily nutrients’ composition of parenteral (compounded or
industrial) mixtures, per kg of body weight, prescribed in 298 HPN
patients followed in 2011 at Federico II Home Artificial Nutrition Unit
(mean and 95% confidence interval)
Nutrient PPNMs
n¼ 68
Mean (95% CI)
SPNMs
n¼ 230
Mean (95% CI)
Calories (kcal/kg per day) 21 (19–23) 23 (22–24)
Fluid (ml/kg per day) 38 (34–41)a 30 (29–31)
Nitrogen (g/kg per day) 0.16 (0.14–0.17)a 0.12 (0.11–0.13)
Amino acid (g/kg per day) 1.04 (0.94–1.13)a 0.78 (0.74–0.81)
Glucose (g/kg per day) 2.8 (2.5–3.1)a 2.3 (2.2–2.4)
Lipids (g/kg per day) 0.7 (0.6–0.8)a 1.1 (1.0–1.1)
Sodium (mmol/kg per day) 1.9 (1.6–2.2)a 0.8 (0.7–0.8)
Potassium (mmol/kg per day) 0.73 (0.57–0.90)a 0.55 (0.53–0.58)
Magnesium (mmol/kg per day) 0.16 (0.13–0.18)a 0.08 (0.08–0.09)
Calcium (mmol/kg per day) 0.09 (0.07–0.10)a 0.05 (0.04–0.05)
Phosphorus (mmol/kg per day) 0.19 (0.14–0.24)a 0.25 (0.24–0.26)
Abbreviations: CI, confidence interval; HPN, home parenteral nutrition;
PPNMs, personalized parenteral nutrition mixtures; n, number of patients
on HPN treated by compounded or industrial mixtures; SPNMs, standard
parenteral nutrition mixtures. aSignificant difference with industrial
mixture (Po0.01, Mann–Whitney test).
Table 4. Nutrients (per kg of body weight per day) in parenteral mixtures (compounded or industrial) prescribed for HPN patients, classified
according to their primary disease
Cancer CIF Other diseases
PPNMs (n¼ 47) SPNMs (n¼ 186) PPNMs (n¼ 16) SPNMs (n¼ 18) PPNMs (n¼ 5) SPNMs (n¼ 26)
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Calories (kcal/kg per day) 19 (16–21)a 22 (21–24) 26 (20–31) 24 (21–27) 24 (15–33) 22 (19–26)
Fluid (ml/kg per day) 34 (30–37)b 30 (28–31) 47 (39–55)a 29 (26–33) 44 (28–60)a 30 (25–34)
Nitrogen (g/kg per day) 0.14 (0.13–0.16)a 0.12 (0.11–0.12) 0.19 (0.16–0.23)a 0.13 (0.11–0.15) 0.16 (0.03–0.30) 0.12 (0.10–0.14)
Amino acid (g/kg per day) 0.94 (0.84–1.04)a 0.77 (0.73–0.81) 1.28 (1.04–1.51)a 0.85 (0.72–0.98) 1.06 (0.16–1.96) 0.76 (0.64–0.88)
Glucose (g/kg per day) 2.5 (2.2–2.8) 2.3 (2.1–2.4) 3.4 (2.6–4.3)b 2.5 (2.1–3.0) 2.9 (1.5–4.2) 2.2 (1.9–2.6)
Lipids (g/kg per day) 0.6 (0.5–0.7)a 1.1 (1.0–1.1) 0.8 (0.6–1.1) 1.1 (1.0–1.2) 1.0 (0.6–1.4) 1.1 (0.9–1.2)
Sodium (mmol/kg per day) 1.6 (1.3–1.8)a 0.8 (0.7–0.8) 2.8 (2.1–3.5)a 0.8 (0.7–1.0) 2.0 (1.2–2.8)a 0.7 (0.6–0.9)
Potassium (mmol/kg per day) 0.5 (0.4–0.7) 0.6 (0.5–0.6) 1.4 (1.0–1.8)a 0.6 (0.5–0.7) 0.4 (0.0–1.3) 0.5 (0.4–0.6)
Magnesium (mmol/kg per day) 0.11 (0.09–0.13)b 0.08 (0.08–0.09) 0.25 (0.17–0.33)a 0.09 (0.08–0.10) 0.23 (0.08–0.38)a 0.08 (0.07–0.09)
Calcium (mmol/kg per day) 0.07 (0.06–0.08)a 0.05 (0.05–0.05) 0.14 (0.11–0.17)a 0.06 (0.05–0.07) 0.08 (0.04–0.12) 0.05 (0.04–0.06)
Phosphorus (mmol/kg per day) 0.13 (0.09–0.16)a 0.24 (0.23–0.26) 0.38 (0.28–0.49) 0.27 (0.23–0.31) 0.07 (0.00–0.21)a 0.24 (0.21–0.28)
Abbreviations: CI, confidence interval; CIF, chronic intestinal failure; HPN, home parenteral nutrition; n, number of patients on HPN treated by compounded or
industrial mixture; PPNMs, personalized parenteral nutrition mixtures; SPNMs, standard parenteral nutrition mixtures. Mean and 95% CI. aSignificant difference
with industrial mixtures in the same patients’s group (Po0.01, Mann–Whitney test). bSignificant difference with industrial mixtures in the same patients’s
group (Po0.05, Mann–Whitney test).
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In conclusion, the study does not answer the important
question of whether personalized mixtures for PN are more
appropriate than standard ones, at least in speciﬁc clinical
conditions. Although this study is only an illustration of current
practice patterns, it demonstrates that in some selective cases
PPNM composition is different from the standard ones, in
particular when the patient is clinically and metabolically instable.
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